Irodalom:
Bioulac-Sage, P. et al.: “Genotype phenotype classification of hepatocellular adenoma.” World
J.Gastroenterol. 13.19 (2007): 2649-54.
Bioulac-Sage, P. et al.: “Hepatocellular adenoma subtype classification using molecular markers and
lmmunohistochemistry.” Hepatology 46.3 (2007): 740-48.
Bioulac-Sage, P. et al.: “Diagnostic value of glutamine synthase to differentiate focal nodular hyperplasia
(FNH) from hepatocellular adenoma (HCA) and carcinoma.” Hepatology 46.4 (2007): 431A.
Boyault, S. et al.: “Transcriptome classification of HCC is related to gene alterations and to new
therapeutic targets.” Hepatology 45.1 (2007): 42-52.
Bravi, F. et al.: “Coffee drinking and hepatocellular carcinoma risk: a meta-analysis.” Hepatology 46.2
(2007): 430-35.
Di Tommaso, L. et al.: “Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular
nodules in cirrhosis.” Hepatology 45.3 (2007): 725-34.
Evans, M. J. et al.: “Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry.” Nature
446.7137 (2007): 801-05.
Paradis, V. et al:. “Telangiectatic adenoma: an entity associated with increased body mass index and
inflammation.” Hepatology 46.1 (2007): 140-46.
Rebouissou, S., P. Bioulac-Sage, and J. Zucman-Rossi.: “Molecular pathogenesis of focal nodular
hyperplasia and hepatocellular adenoma.” J.Hepatol. 48.1 (2008): 163-70.
Reynolds, G. M. et al.: “Hepatitis C virus receptor expression in normal and diseased liver tissue.”
Hepatology 47.2 (2008): 418-27.
Wurmbach, E. et al.: “Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular
carcinoma.” Hepatology 45.4 (2007): 938-47.
